These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8944989)

  • 1. Optimization and assessment of the in vivo efficacy of a heparin removing bio-reactor using mathematical modeling.
    Byun Y; Wang T; Kim JS; Yang VC
    ASAIO J; 1996; 42(5):M782-7. PubMed ID: 8944989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of immobilized protamine in removing heparin and preventing protamine-induced complications during extracorporeal blood circulation.
    Yang VC; Port FK; Kim JS; Teng CL; Till GO; Wakefield TW
    Anesthesiology; 1991 Aug; 75(2):288-97. PubMed ID: 1859016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A protamine filter for extracorporeal heparin removal. Development, testing, blood compatibility evaluation, and future direction.
    Byun Y; Yun JH; Han IS; Fu Y; Shanberge JN; Yang VC
    ASAIO J; 1995; 41(3):M301-5. PubMed ID: 8573812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A protamine filter for extracorporeal blood heparin removal.
    Teng CL; Kim JS; Port FK; Wakefield TW; Till GO; Yang VC
    ASAIO Trans; 1988; 34(3):743-6. PubMed ID: 3196594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A filter device for the prevention of both heparin- and protamine-induced complications associated with extracorporeal therapy.
    Yang VC; Teng CL; Kim JS
    Biomed Instrum Technol; 1990; 24(6):433-9. PubMed ID: 2261582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strategies for improving the functionality of an affinity bioreactor.
    Wang T; Yang Z; Emregul E; David A; Balthasar JP; Liang J; Yang VC
    Int J Pharm; 2005 Dec; 306(1-2):132-41. PubMed ID: 16246511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of protamine hollow-fiber device for extracorporeal heparin removal.
    Liang JF; Emregul E; Yang VC
    Blood Purif; 2004; 22(2):198-202. PubMed ID: 15044818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin clearance profiles after systemic anticoagulation using a heparin removal device system.
    Tao W; Callahan JD; Vertrees RA; Brunston RL; Deyo DJ; McRea JC; Zwischenberger JB
    ASAIO J; 1997; 43(6):922-6. PubMed ID: 9386844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel approach for optimizing the capacity and efficacy of a protamine filter for clinical extracorporeal heparin removal.
    Zhang Y; Singh VK; Yang VC
    ASAIO J; 1998; 44(5):M368-73. PubMed ID: 9804453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of a heparin removal device in comparison with protamine after hypothermic cardiopulmonary bypass.
    Tao W; Deyo DJ; Brunston RL; Vertrees RA; Grochoske TL; Zwischenberger JB
    ASAIO J; 1997; 43(5):M825-30. PubMed ID: 9360162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel approach to anticoagulation control.
    Kim JS; Vincent C; Teng CL; Wakefield TW; Yang VC
    ASAIO Trans; 1989; 35(3):644-6. PubMed ID: 2597555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracorporeal heparin adsorption following cardiopulmonary bypass with a heparin removal device--an alternative to protamine.
    Tao W; Deyo DJ; Brunston RL; Vertrees RA; Zwischenberger JB
    Crit Care Med; 1998 Jun; 26(6):1096-102. PubMed ID: 9635661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow rate dependent ex vivo deheparinization with immobilized cationic ligand.
    Tevaearai HT; Mueller XM; Marty B; Horisberger J; Schapira M; von Segesser LK
    ASAIO J; 1997; 43(5):M487-9. PubMed ID: 9360090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficiency of polymer beads in the removal of heparin: toward the development of a novel reactor.
    Varghese MS; Hildebrandt D; Glasser D; Crowther NJ; Rubin DM
    Artif Cells Blood Substit Immobil Biotechnol; 2006; 34(4):419-32. PubMed ID: 16818415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Coagulation patterns during deheparinization with immobilized polycation.
    von Segesser LK; Mihailevic T; Tönz M; Leskosek B; von Felten A; Turina M
    ASAIO J; 1994; 40(3):M565-9. PubMed ID: 8555578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of anticoagulation without protamine using a heparin removal device after cardiopulmonary bypass.
    Vertress RA; Zwischenberger JB; McRea JC; Tao W; Kurusz M; Conti VR
    ASAIO J; 1994; 40(3):M560-4. PubMed ID: 8555577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of protamine of the prolonged response to intrapulmonary heparin.
    Wright CJ; Mahadoo J; Jaques LB
    Can J Surg; 1981 Mar; 24(2):130-2. PubMed ID: 7225967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation.
    Massonnet-Castel S; Pelissier E; Bara L; Terrier E; Abry B; Guibourt P; Swanson J; Jaulmes B; Carpentier A; Samama M
    Haemostasis; 1986; 16(2):139-46. PubMed ID: 3710291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin-protamine complexes in the production of heparin rebound and other complications of extracorporeal bypass procedures.
    Shanberge JN; Murato M; Quattrociocchi-Longe T; van Neste L
    Am J Clin Pathol; 1987 Feb; 87(2):210-7. PubMed ID: 3812352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assembly of the Heparin Removal Device for patients with suspected adverse reaction to protamine sulphate.
    Jegger D; Tevaerai HT; Horisberger J; Mueller XM; Seigneuil I; Pierrel N; Boone Y; von Segesser LK
    Perfusion; 2000 Sep; 15(5):453-6. PubMed ID: 11001169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.